News

March 21, 2011

APIM Therapeutics announced today conclusion of a second seed follow up financing round by Sarsia Seed, a Norwegian seed stage life science fund. Financing will be used to advance the preclinical investigation of APIM Therapeutics' lead compound in further cancer in vivo studies, predominantly in Myeloma and Acute Myeloid Leukemia. For more information, please visit: http://www.prnewswire.co.uk/cgi/news/release?id=315415

May 27, 2010

APIM Therapeutics announced today that Sarsia Seed, a Norwegian seed stage life science fund, has invested NOK 3.5 million (€ 440.000) in APIM Therapeutics. The company, a spin-out from the Norwegian University of Science and Technology (NTNU), is developing novel peptide drugs which have the potential to improve clinical outcomes achieved with a large group of existing first line chemotherapeutics.